GALDERMA
19.3.2024 07:01:34 CET | Business Wire | Press release
Galderma will present the latest updates from its broad portfolio of clinically-proven and holistic range of aesthetic treatments at the 22nd Aesthetic & Anti-Aging Medicine World Congress (AMWC) on March 27-29, 2024. The diversity of Galderma’s portfolio, designed to meet the individual needs of healthcare professionals and patients, will be showcased in 16 research posters – including data from the world’s most diverse range of fillers (Restylane®), leading neuromodulator portfolio (RelabotulinumtoxinA, Alluzience® and Azzalure®) and original biostimulator (Sculptra®) – as well as two symposia and a booth, which will host an array of live demonstrations and ‘Meet the Expert’ sessions.
“Galderma’s extensive activities at AMWC demonstrate our commitment to pushing the boundaries of injectable aesthetics, to anticipate and address tomorrow’s needs today. By evolving and expanding our existing treatments, developing new innovations, and conducting cutting-edge research into the groundbreaking trends that are anticipated to drive the future of aesthetics, our future-facing approach ensures we continue to deliver the best for healthcare professionals and patients.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA
|
|
Educating on the future of aesthetics and Sculptra’s expanding indications
The Galderma-sponsored symposium, The AART™ and Science behind NEXT, will host a panel of world-renowned aesthetic experts, including Dr. Sebastian Cotofana, Dr. Alessandra Haddad, Dr. Christoph Martschin, Dr. Andreas Nikolis, Dr. Sachin Shridharani, and Dr. Van Park, who will delve into the six identified groundbreaking trends that are anticipated to drive the future of aesthetics and how they will impact consultation and interaction with patients. A live demonstration will show how to best integrate the trends’ insights in practice via Galderma’s holistic assessment tool, the AART methodology, and create bespoke treatment plans for patients. The event is taking place in Room Prince Pierre on Wednesday March 27, 2024, from 2:00 to 4:00 PM CET.
As we celebrate 25 years of science and expertise in biostimulation with Sculptra, Galderma’s second symposium, The AART™ of Sculptra beyond the face, will focus on how to use the AART assessment tool to address patients’ body concerns and needs. Prominent experts in the field, including Dr. Luiz Avelar, Dr. Sebastian Cotofana, Dr. Alessandra Haddad, and Dr. Marcus Morais, will focus on how to assess and treat the gluteal (buttock) region to address different patient profiles with Sculptra treatment. Through clinical cases, they will also touch on Sculptra’s use on the décolletage, neck and upper arms. The event is taking place in Room Van Dongen on Thursday March 28, 2024, from 11:00 to 11:55 AM CET.
Extensive data spotlight how Galderma is advancing dermatology for every skin story
Pivotal clinical data supporting the safe and effective use of Restylane SHAYPE™ for augmentation and correction of chin retrusion, with clinical results sustained for up to 12 months, will be presented.1 Restylane SHAYPE is the latest innovation in hyaluronic acid (HA) injectables, powered by new NASHA HD™ technology, the next generation in HA science. Restylane SHAYPE is engineered to shape angles in the lower face by providing a bone mimicking effect.1 It is the newest addition to the Restylane portfolio, the world’s most diverse range of fillers with over 27 years of clinical data, which encompasses different technologies (NASHA®, OBT™ and now NASHA HD) and gel characteristics, with solutions available to meet the needs of patients and injectors all over the world.4 Additional data from studies of Restylane VOLYME™ and EYELIGHT™ will be shared for midface augmentation and correction of infraorbital hollows (dark under-eye shadows and grooves), respectively, with improvements maintained through to 12 months.5,6
New data from the phase III READY-1 and READY-2 studies will also be presented, showing high patient-reported satisfaction and improved wellbeing through six months after treatment with RelabotulinumtoxinA for glabellar lines (frown lines) and lateral canthal lines (crow’s feet).2,3 The treatment was well tolerated and improvement in frown line and crow’s feet severity and aesthetic appearance was maintained through six months.2,3 Developed using Galderma’s proprietary PEARLTM technology, RelabotulinumtoxinA is a highly-active, ready-to-use solution that delivers fast and sustained results and maximizes ease-of-use to address the real needs of patients and healthcare professionals.7-19
Six posters on Sculptra, the first and original biostimulator, with a unique PLLA-SCA™ formulation that activates the body's natural power to revitalize key components of the skin for a more youthful appearance, will be presented at AMWC. Additional data spanning our leading neuromodulator portfolio, Alluzience and Azzalure, will be presented, as well as a new skin quality assessment scale and the AART-HIT™ approach for combining aesthetic products to maximize patient outcomes.
More details on scientific presentations supported by Galderma at AMWC can be found here.*
*All presenters are paid consultants or employees of Galderma. |
About the Restylane® Portfolio
With more than 27 years of experience, over 160 clinical publications, and trusted with 65 million treatments and growing worldwide, the Restylane portfolio’s three complementary gel technologies – NASHA®, OBT™ and NASHA HD™ – allow for individualized, natural-looking results and long-term patient satisfaction.4,20,21 The uniqueness and complementary nature of the Restylane portfolio allows for individualized, natural-looking results, providing long-lasting improvement and long-term satisfaction for patients’ self-confidence.4,20-23
About RelabotulinumtoxinA (QM1114)
Developed by Galderma, RelabotulinumtoxinA is a highly-active, innovative, complex-free, and ready-to-use liquid neuromodulator with a proprietary strain and manufactured using a unique state-of-the-art process. It is designed as a liquid, avoiding the traditional requirement to reconstitute from powder and eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency of results. RelabotulinumtoxinA is currently being investigated globally by Galderma, to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. RelabotulinumtoxinA is an investigational product and has not received approval for any indication in any country.
About Sculptra®
Sculptra is the original biostimulator and is clinically proven to stimulate the skin's innate collagen (type I) production to increase skin firmness and radiance, for long-lasting, natural-looking rejuvenated appearance. Sculptra is proven to increase collagen type I by 66.5% after three months through a process that starts stimulation as early as five days after injection.24 It helps progressively restore the skin’s foundation and natural structural function. Sculptra is proven to achieve natural-looking results that last for more than two years.25 Sculptra provides targeted collagen stimulation, with unique treatment protocols developed for each treatment area and to achieve the patients’ desired results.
About Galderma
Galderma is the emerging pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market though Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References |
1. Nikolis, A, et al. Effectiveness and Safety of a New NASHA-HD Hyaluronic Acid Injectable, HASHA, for Augmentation and Correction of Chin Retrusion. E-poster presented at AMWC 2024 |
2. Gold, M, et al. Subject-Reported Improvement in Well-Being and High Satisfaction After Glabellar Line Treatment with RelabotulinumtoxinA, an Investigational ready-to-Use Liquid Botulinum Toxin (READY-1 Phase III Trial). E-poster presented at AMWC 2024 |
3. Grunebaum, L, et al. Improved Well-Being and Natural-Looking Results After Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin (READY-2 Phase III Trial). E-poster presented at AMWC 2024 |
4. Carlo Di Gregorio. 25+ Years of Experience with the Restylane Portfolio of Injectable Hyaluronic Acid Fillers for Facial Aesthetic Treatment. E-poster presented at AMWC 2024 |
5. Ren, R, et al. Midface Augmentation in Chinese Subjects Using a Flexible Hyaluronic Acid Filler Evaluated in a Randomized No-treatment Controlled Study. E-poster presented at AMWC 2024 |
6. Biesman, B, et al. A Study Evaluating the Safety and Effectiveness of Hyaluronic Acid Filler HAEYE for Correction of Infraorbital Hollows (IOH, Tear Trough Study). E-poster presented at AMWC 2024 |
7. Galderma. Data on file. Clinical Study Report for Protocol 43QM1602: READY-1. Galderma Laboratories; 2021 |
8. Galderma. Data on file. Clinical Study Report for Protocol 43QM1901: READY-2. Galderma Laboratories; 2021 |
9. Galderma. Data on file. READY-2 Post-hoc Tables. Galderma Laboratories; 2021 |
10. Galderma. Data on file. Clinical Study Report for Protocol 43QM1902: READY-3. Galderma Laboratories; 2021 |
11. Galderma. Data on file. Clinical Study Report for Protocol 43AM1903: READY-4. Galderma Laboratories; 2021 |
12. Galderma. Data on file: Initial results of the phase IIIb 43QM2106 trial; 2023 |
13. Galderma. Data on file: Initial results of the phase IIIb 43QM2107 trial; 2023 |
14. Solish, N, et al. Treatment of Moderate-to-Severe Glabellar Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-1 Phase III trial. Abstract presented at TOXINS 2024 |
15. Ablon, G, et al. Treatment of Lateral Canthal Lines with RelabotulinumtoxinA, an Investigational Liquid Botulinum Toxin: Clinical Efficacy and Safety Results from the READY-2 Phase III Trial. Abstract presented at TOXINS 2024 |
16. Bertucci, V, et al. Efficacy and Safety of a Novel Formulation Liquid Botulinum Toxin, RelabotulinumtoxinA, when used for Combination Treatment of Glabellar and Lateral Canthal Lines. Abstract presented at TOXINS 2024 |
17. Persson, C, et al. Patient and Investigator Treatment Experience with Ready-to-Use AbobotulinumtoxinA Solution Versus Powder BotulinumtoxinA for Treatment of Glabellar Lines. Abstract presented at TOXINS 2024 |
18. Sundberg, AL, and Stahl, U. Relabotulinum toxin - a novel, high purity BoNT-A1 in liquid formulation. Presented at: TOXINS 2021 |
19. Do, M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) - relabotulinumtoxinA. Presented at: TOXINS 2022 |
20. Nikolis, A, et al. The Role of Clinical Examination in Midface Volume Correction Using Hyaluronic Acid Fillers: Should Patients Be Stratified by Skin Thickness? Aesthet Surg J Open Forum. 2020; 2(1):1–12. |
21. Galderma. Data on file. Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021 |
22. Narins, RS, et al. Persistence of nasolabial fold correction with a hyaluronic acid dermal filler with retreatment: results of an 18-month extension study. Dermatol Surg. 2011;37:644–650 |
23. Talarico, S, et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41:1361–1369 |
24. Goldberg, D, Guana, A, Volk, A, Daro-Kaftan, E. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. Dermatol Surg. 2013;39(6):915-922 |
25. Fabi, S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at AMWC 2023 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318297749/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom